series of novel pyrazolo[3,4-d]pyrimidin-4-one derivatives were synthesized and evaluated for their anti-phosphodiesterase-5 (PDE-5) activity. A total of 28 compounds, containing alkyl and aryl groups at the 1-N and 3-C positions on the pyrazole ring, and also bearing different alkyl substituents on the piperazine ring were synthesized. Four compounds (4d, 5d, 6d, and 5o) were found to have better
[EN] THIOPHENE AND FURAN COMPOUNDS<br/>[FR] COMPOSES DE THIOPHENE ET DE FURANE
申请人:LILLY CO ELI
公开号:WO2005070916A1
公开(公告)日:2005-08-04
The present invention relates to thiophene and furan compounds and their pharmaceutically acceptable salts, and further relates to their use in treating schizophrenia, cognitive deficits associated with schizophrenia, Alzheimer's disease, dementia of the Alzheimer's type, mild cognitive impairment, or depression.
[EN] PYRAZOLOPYRIMIDINES AS KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASE SOUS FORME DE PYRAZOLOPYRIMIDINES
申请人:SMITHKLINE BEECHAM CORP
公开号:WO2004009602A1
公开(公告)日:2004-01-29
The present invention relates generally to inhibitors of the kinases and more particularly to novel pyrazolopyrimidine compounds.
本发明一般涉及激酶的抑制剂,更具体地涉及新型吡唑吡嘧啶化合物。
[EN] PYRROLE AND PYRAZOLE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS<br/>[FR] COMPOSES DE PYRROLE ET PYRAZOLE PRESENTANT UN EFFET POTENTIATEUR SUR LES RECEPTEURS DU GLUTAMATE
申请人:LILLY CO ELI
公开号:WO2005040110A1
公开(公告)日:2005-05-06
The present invention relates to pyrrole and pyrazole compounds of formula (I) and their pharmaceutically acceptable salts, and further relates to their use in treating schizophrenia, cognitive deficits associated with schizophrenia, Alzheimer's disease, dementia of the Alzheimer's type, mild cognitive impairment, or depression. The compounds act as potentiators on glutamate receptors, in particular AMPA and the GluR family.
6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and
申请人:Sterling Winthrop Inc.
公开号:US05294612A1
公开(公告)日:1994-03-15
Novel 6-heterocyclyl-pyrazolo[3,4-d]pyrimidin-4-ones, useful in treating cardiovascular disease, are prepared by reacting a 5-amino-1H-pyrazole-4-carboxamide with heterocyclylcarboxaldehyde or by reacting a 5-amino-1H-pyrazole-4-carbonitrile with a heterocyclylcarboxamidine, followed by diazotization and hydrolysis of the resulting 4-amino-6-heterocyclyl-pyrazolo[3,4-d]pyrimidine.